TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 13nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 18nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 22nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 22nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 31nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 45nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 52nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 54nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 100nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 120nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 130nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 140nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 150nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 150nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 160nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 160nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 180nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 200nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 210nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 210nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 220nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 270nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 280nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 310nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 330nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 340nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 370nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 400nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 410nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 410nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 420nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 480nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 500nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 520nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 550nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 740nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 910nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 1.20E+3nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 1.50E+3nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
TargetIntegrin alpha-4/Integrin beta-1/Vascular cell adhesion protein 1(Homo sapiens (Human))
EA Pharma Co., Ltd.
US Patent
EA Pharma Co., Ltd.
US Patent
Affinity DataIC50: 1.50E+3nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human T-cell line, Jurkat, which is known to express α4β1 integrin, to VCAM-1 w...More data for this Ligand-Target Pair
